After obtaining his Engineer Degree in Agronomy (1984), Guillaume Cottarel spend a sabbatical year at the Molecular Genetic Center of the CNRS. He then obtained his PhD in Molecular Biology and Microbiology (1989) at the University of Giessen Germany, from where he went to Cold Spring Harbor Laboratory for three years to make his post-doctoral fellowship as a Howard Hughes Medical Institute Research Associate. In 1992, he moved to Cambridge, MA as member of the founding team of Mitotix Inc, a start-up working to develop novel therapeutics against proliferative diseases (cancer, anti-infective) using the Cell Cycle Control expertise. In 1995, he joined Genome Therapeutics Corporation to lead genomics and high-throughput research programs financed by big pharmaceutical companies; in his final role there he supervised numerous scientific projects and led the Functional Genomics Center of Expertise. In 2003, Guillaume Cottarel joined Cellicon Biotechnologies Inc, a start-up company based at Boston University, where he also holds a Research Faculty Position. Cellicon is a Systems Biology driven biotechnology using functional genomics platforms and mathematical algorithms to fully characterized pathways in response to perturbations. Such perturbations include up and down regulation of genes as well as response to compounds.